Evolus Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Evolus de 65.1% y 23.1% respectivamente, mientras que el BPA crecerá en un 65.2% al año.

Información clave

65.1%

Tasa de crecimiento de los beneficios

65.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.0%
Tasa de crecimiento de los ingresos	23.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	17 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Recent updates

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:EOLS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	446	42	103	113	6
12/31/2025	344	-9	22	34	7
12/31/2024	263	-37	-38	-18	7
12/31/2023	202	-62	-36	-34	N/A
9/30/2023	185	-63	-46	-44	N/A
6/30/2023	169	-66	-63	-60	N/A
3/31/2023	156	-72	-70	-67	N/A
12/31/2022	149	-74	-88	-85	N/A
9/30/2022	140	-79	-87	-85	N/A
6/30/2022	132	-79	-101	-100	N/A
3/31/2022	121	-71	-64	-63	N/A
12/31/2021	100	-47	-34	-33	N/A
9/30/2021	86	-139	-27	-27	N/A
6/30/2021	77	-131	-10	-8	N/A
3/31/2021	58	-137	-40	-38	N/A
12/31/2020	57	-163	-61	-58	N/A
9/30/2020	55	-67	-76	-72	N/A
6/30/2020	51	-82	-87	-83	N/A
3/31/2020	45	-99	-107	-102	N/A
12/31/2019	35	-90	-98	-93	N/A
9/30/2019	15	-88	-93	-89	N/A
6/30/2019	2	-73	-73	-70	N/A
3/31/2019	N/A	-52	-43	-43	N/A
12/31/2018	N/A	-47	-26	-26	N/A
9/30/2018	N/A	-30	-15	-15	N/A
6/30/2018	N/A	-21	-12	-12	N/A
3/31/2018	N/A	-7	-10	-10	N/A
12/31/2017	N/A	-4	-13	-13	N/A
9/30/2017	N/A	-13	N/A	-14	N/A
6/30/2017	N/A	-14	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-14	N/A
12/31/2016	N/A	-20	N/A	-13	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que EOLS sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que EOLS sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que EOLS sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (23.1% al año) de EOLS crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (23.1% al año) de EOLS crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de EOLS se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Evolus Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. Announces Earnings Guidance for 2024

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Recent updates

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Independent Director notifies of intention to sell stock

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

President notifies of intention to sell stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$20.25

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Price target increased by 9.4% to US$18.11

Consensus EPS estimates fall by 46%

Price target increased by 8.4% to US$17.22

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings: EPS misses analyst expectations

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Evolus: Turning That Frown Upside Down

Independent Director recently bought US$91k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Evolus appoints Experian's exec as CFO

Consensus forecasts updated

Forecast to breakeven in 2024

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022

Insufficient new directors

Evolus Q2 2022 Earnings Preview

Evolus, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Evolus, Inc. Completes Patient Enrollment in Phase II Clinical Study Evaluating Extra-Strength Dose of Jeuveau

Evolus, Inc. Announces Dermatologic Surgery Published A New Post Hoc Analysis of Its Phase III Studies Comparing Millennial Patients to Non-Millennials

Independent Director notifies of intention to sell stock

Independent Director recently sold US$138k worth of stock

Evolus, Inc. Revises Earnings Guidance for the Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau